Northwest Biotherapeutics ( (NWBO) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Northwest Biotherapeutics, Inc. has filed a Form 12b-25 to notify investors that it will delay its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The company’s annual filing for this period will therefore not arrive on the original SEC deadline.
Management says the delay stems from complex accounting issues tied to its acquisition of Advent BioServices. The work involves reconciling differences between UK GAAP and U.S. GAAP, which has complicated the final stages of the Form 10-K (Yearly Report) preparation.
The company has indicated it expects to file the Form 10-K (Yearly Report) within the standard 15-day extension window allowed under Form 12b-25. It also states that it is working to complete and submit the 2025 Annual Report as soon as reasonably practicable.
Northwest Biotherapeutics does not expect any significant changes in results of operations versus the prior year based on the information currently available. The company also cautions that any statements about timing and expectations are forward-looking and subject to audit completion and other uncertainties.
The firm notes that all other required periodic filings over the past 12 months have been made on time, underscoring an otherwise clean reporting record. The notification was signed on March 31, 2026, by Chief Executive Officer and Chairman Linda F. Powers, signaling ongoing efforts to remain in compliance with SEC reporting rules.
More about Northwest Biotherapeutics
Average Trading Volume: 2,791,715
Technical Sentiment Signal: Sell
Current Market Cap: $304.3M
For detailed information about NWBO stock, go to TipRanks’ Stock Analysis page.